Results 241 to 250 of about 1,530,452 (285)
Some of the next articles are maybe not open access.

Live attenuated tetravalent dengue vaccine

Vaccine, 2000
The development of a live attenuated tetravalent dengue vaccine is currently the best strategy to obtain a vaccine against dengue viruses. The Mahidol University group developed candidate live attenuated vaccines by attenuation through serial passages in certified primary cell cultures.
N, Bhamarapravati, Y, Sutee
openaire   +2 more sources

Immunization with Live Attenuated Poliovirus Vaccine

Archives of Pediatrics & Adolescent Medicine, 1961
Live attenuated poliovirus vaccine was administered to 400 newborn infants during a three-month period (October, 1959, to January, 1960). This study was designed to obtain information which might provide answers to the following questions. Would the ingestion of larger doses permit enough of the vaccine viruses regularly to pass the "acid barrier" of ...
S, KRUGMAN   +5 more
openaire   +2 more sources

A Trial With Live Attenuated Rubella Vaccine

Archives of Pediatrics & Adolescent Medicine, 1968
CONTROLLED trials of a high passage rubella virus strain conducted by Meyer et al in institutionalized human subjects 1 indicated that the virus was attenuated, immunogenic, and did not spread from vaccinees to others. The present investigation was undertaken to extend these observations in younger institutionalized subjects.
M L, Lepow   +3 more
openaire   +2 more sources

Live attenuated influenza vaccine

2008
The development of the live, attenuated influenza vaccine (LAIV), based on the cold-adapted (ca), attenuated ca A/Ann Arbor/6/60 and ca B/Ann Arbor/1/66 backbones, has spanned several decades. The vaccine contains three vaccine strains, two attenuated influenza A strains and one attenuated influenza B strain; these vaccine strains are genetic ...
Harry Greenberg, George Kemble
openaire   +1 more source

An Attenuated Live Virus Vaccine for Myxomatosis

Nature, 1964
MYXOMATOSIS has been recognized as a virus disease since 18981. Although the disease is uniformly fatal, efforts to develop an effective, practical method of prevention have met with indifferent success.
D G, MCKERCHER, J K, SAITO
openaire   +2 more sources

Live Attenuated Influenza Vaccine in Children

Seminars in Pediatric Infectious Diseases, 2006
Live attenuated influenza vaccine (LAIV) offers a novel approach to influenza vaccination and is approved for healthy individuals 5 to 49 years of age. In placebo-controlled studies in children, LAIV was 73 to 93 percent efficacious, and protection lasted more than 12 months.
Christopher S, Ambrose   +2 more
openaire   +2 more sources

Vaccination with Live Attenuated Measles Virus

Archives of Pediatrics & Adolescent Medicine, 1962
Introduction Isolation of the virus of measles in human tissue culture and its subsequent adaptation to growth in embryonated eggs and chick embryo cell culture by Enders and his colleagues 1-3 has led to the rapid development in the United States of vaccines suitable for use in the immunoprophylaxis of this disease.
R B, HORNICK   +2 more
openaire   +2 more sources

A live attenuated human rotavirus vaccine

Drugs of Today, 2007
Rotavirus infections are the leading cause of severe gastroenteritis in young children worldwide. This review provides a summary of the development of a live oral rotavirus vaccine, Rotarix (GlaxoSmithKline, Rixensart, Belgium) developed from a single protective G1P[8] human strain.
openaire   +2 more sources

Live, Attenuated Rubella-Virus Vaccine

New England Journal of Medicine, 1968
HIGH priority is being given in the United States and Europe to the development of an effective live, attenuated rubella (German-measles) virus vaccine.
M R, Hilleman   +3 more
openaire   +2 more sources

Live Attenuated Varicella-Zoster Vaccine

Clinical Infectious Diseases, 1980
Varicella-zoster (VZ) virus causes two diseases, varicella and zoster. Because it was recognized that, after varicella, latent VZ virus persisted in the host and because varicella was thought to be a milde disease, there was little impetus in North America to develop a live VZ vaccine.
openaire   +2 more sources

Home - About - Disclaimer - Privacy